Abstract. The expression of is significantly reduced in cancer tissues of maxillary sinus squamous cell carcinoma (MSSCC). The aim of this study was to investigate the functional significance of miR-375 and a possible regulatory role in the MSSCC networks. Restoration of miR-375 significantly inhibited cancer cell proliferation and invasion in IMC-3 cells, suggesting that miR-375 functions as a tumor suppressor in MSSCC. Genome-wide gene expression data and luciferase reporter assays indicated that lactate dehydro genase B (LDHB) was directly regulated by miR-375. Cancer cell proliferation and invasion were significantly inhibited by transfection of si-LDHB into IMC-3 cells, suggesting that LDHB may play a role in MSSCC oncogenic function. In clinical MSSCC specimens, LDHB mRNA levels were up-regulated in cancer tissues, which were inversely correlated with the expression of miR-375. In addition, Kaplan-Meier curves and log-rank tests revealed that the high mRNA expression levels of LDHB had a significant adverse effect on survival rate. The identification of a cancer network regulated by the miR-375 tumor suppressor could provide new insights into the molecular mechanisms of MSSCC oncogenesis.
Introduction
Maxillary sinus squamous cell carcinoma (MSSCC) is a malignant epithelial tumor originating in the respiratory mucosa of the maxillary sinus. MSSCC comprises 2-3% of all head and neck tumors, with an annual incidence of 0.5-1.0 per 100,000 people (1, 2) . Since the clinical symptoms of patients with MSSCC are very insidious, tumors are often diagnosed at advanced stages. Despite advances in multimodality therapy including surgery, radiotherapy and chemotherapy, the 5-year survival rate for MSSCC has remained ~50%. Although regional lymph node metastasis and distant metastasis are uncommon (20%), the high rate of locoregional recurrence (60%) contributes to poor survival (3). The results of epidemiological studies have suggested that occupational exposures to leather, wood dust, nickel, arsenic and formaldehyde are risk factors for MSSCC (4-6); a point of divergence from head and neck squamous cell carcinomas (HNSCC) of the tongue, oral cavity and pharynx. Few reports have performed genome analysis of MSSCC. Understanding the molecular oncogenic pathways underlying MSSCC could significantly improve diagnosis, therapy, and disease prevention.
Growing evidence suggests that carcinogenesis is induced by overactivation of pro-oncogenic pathways and inactivation of tumor-suppressive pathways (7) . In cancer pathways, normal regulatory mechanisms are disrupted by aberrant expression of microRNA (miRNA) (8) . miRNAs are a class of small non-coding RNA molecules consisting of [19] [20] [21] [22] nucleotides that are involved in a variety of biological processes including development, differentiation, apoptosis, and cell proliferation. They regulate gene expression through translational repression and mRNA cleavage (9) . Bioinformatic predictions indicate that miRNAs regulate >30% of protein coding genes (10) . So far, 1424 human miRNAs have been registered at miRBase release 17.0 (http://microrna.sanger.ac.uk/). miRNAs contribute to the initiation and development of various types of cancers (11) . miRNAs are aberrantly expressed in many human cancers, and can function either as tumor suppressors or oncogenes (12) . Down-regulated miRNAs in cancer cells might normally function as tumor suppressive miRNAs that negatively regulate oncogenes. Based on this hypothesis, we have profiled the miRNA expression signatures of human cancers, including HNSCC (13) (14) (15) (16) (17) Functional Genomics, miR-489 were identified through direct repression of several oncogenes (15, 16, (18) (19) (20) . The miRNA expression signatures of hypopharyngeal SCC, esophageal SCC and MSSCC revealed that miR-375 is significantly reduced in cancer cells (15, 16) . miR-375 was originally cloned and identified as an evolutionarily conserved pancreatic islet-specific miRNA (21) . miR-375 -/-mice were hyperglycemic and exhibited an increase in the number of pancreatic α cells (22) . Although several studies have indicated that miR-375 is down-regulated in human cancers, the function of miR-375 and its target genes in MSSCC remains unclear (23) (24) (25) (26) .
The aim of this study was to clarify the functional significance of miR-375 in MSSCC and to identify molecular pathways regulated by miR-375. we analyzed the effect of miR-375 on cell proliferation and cell invasion in the MSSCC cell line IMC-3. Genome-wide expression analysis identified lactate dehydrogenase B (LDHB) as a candidate gene target of miR-375. The identification of a novel miR-375-regulated tumor suppressive pathway could further reveal the molecular mechanism of MSSCC oncogenesis.
Materials and methods
MSSCC cell culture. IMC-3, a human MSSCC cell line, was derived from a primary lesion of MSSCC (27) . MSSCC cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37˚C.
Clinical specimens of MSSCC. written consent for tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University. Twenty pairs of primary tumor tissues and corresponding normal epithelial tissues were obtained from patients with MSSCC in Chiba University Hospital (Chiba, japan) from 2007 to 2010. The normal tissue was confirmed to be free of cancer cells by pathologic examination. The specimens were immersed in RNAlater (Qiagen, Valencia, CA, USA) and stored at -20˚C until RNA was extracted. Clinical information of the twenty patients is shown in Table I .
RNA isolation. Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA concentration was determined spectrophoto metrically, and molecular integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Mature miRNA transfection and small interfering RNA treatment. The following RNA species were used in this study: mature miRNAs, Pre-miRTM miRNA Precursors (hsa-miR-375; Pre-miR ID: PM10327), negative control miRNA (P/N: AM17111) (Applied Biosystems, Foster City, CA, USA), small interfering RNA (Stealth Select RNAi™ siRNA; si-LDHB Cat. no.; HSS106003 and HSS106004) (Invitrogen) and negative control siRNA (Stealth™ RNAi Negative Control Medium GC Duplex; 12935-300) (Invitrogen). RNAs were incubated with opti-MeM (Invitrogen) and Lipofectamine™ RNAiMax Reagent (Invitrogen) as described previously (13) . Transfection efficiency of Pre-miRTM in the IMC-3 cell line was confirmed based on down-regulation of TWF1 (PTK9) mRNA following transfection with miR-1 as previously reported (14, 15) .
Cancer cell proliferation and invasion assays. Cells were transfected with 10 nM miRNA and siRNA by reverse transfection and plated in 96-well plates at 3x10 3 cells per well. After 72 or 96 h, cell proliferation was determined with the XTT assay, using the Cell Proliferation kit II (Roche Molecular Biochemicals, Mannheim, Germany) as previously reported (15, 16) . Triplicate wells were measured for cell viability in each treatment group.
A cell invasion assay was carried out using modified Boyden chambers containing transwell-precoated Matrigel membrane filter inserts with 8-µm pores in 24-well tissue culture plates at 1x10 5 cells per well (BD Biosciences, Bedford, MA, USA) (14) . Triplicate wells were measured for cell invasion in each treatment group.
Microarray expression analysis.
A genome-wide screen was performed to identify gene targets of miR-375 in the IMC-3 cell line. oligo-microarray Human 44K (Agilent Technologies) was used for expression profiling of miR-375 transfectants in comparison with miRNA-negative-control transfectants. Microarray hybridization and data collection were performed as previously described (28) . TargetScan (release 5.1, http:// www.targetscan.org/) was used to identify predicted target genes and their miRNA binding site seed regions. Sequences of the predicted mature miRNAs were confirmed using miRBase (release 17.0, http://microrna.sanger.ac.uk/).
Quantitative reverse-transcription-PCR (qRT-PCR).
Firststrand cDNA was synthesized from 1.0 µg of total RNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Gene-specific PCR products were assayed con tinuously using a 7900-HT Real-Time PCR System according to the manu facturer's protocol. TaqMan ® probes and primers for LDHB (P/N: Hs00929956_m1), and GUSB (P/N: Hs99999908_m1) internal control were obtained from Applied Biosystems (Assay-on-Demand Gene expression Products). The expression levels of miR-375 (Assay ID: 000564) was analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to RNU48 (Assay ID: 001006). All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.
Western blot analysis. Cells were harvested and lysed 72 h after transfection. each cell lysate (50 µg of protein) was separated using Mini-PRoTeAN TGX gels (Bio-Rad, Hercules, CA, USA) and transferred to PVDF membranes. Immunoblotting was performed with monoclonal LDHB antibody (1:10000) (2090-1; epitomics, Burlingame, CA, USA). GAPDH antibody (1:1000) (ab8245; AbCam, Cambridge, UK) was used as an internal control. The membrane was washed and incubated with goat anti-rabbit IgG (H+L)-HRP conjugate (Bio-Rad). Complexes were visualized with an Immun-Star westernC chemiluminescence kit (Bio-Rad), and the expression levels of these proteins were evaluated by Imagej software (version 1.44; http://rsbweb.nih.gov/ij/index.html).
Plasmid construction and dual-luciferase reporter assay. The wild-type sequence of the LDHB 3'-UTR (wT-3'UTR) and a sequence with deleted miR-375 target sites (DeL-3'UTR) were inserted between the XhoI-PmeI restriction sites in the 3'UTR of the hRluc gene in the psiCHeCK-2 vector (C8021; Promega, Madison, wI). IMC-3 cells were transfected with 15 ng of vector, 10 nM of miR-375 (Applied Biosystems), and 1 µl of Lipofectamine 2000 (Invitrogen) in 100 µl of opti-MeM (Invitrogen). The activities of Firefly and Renilla luciferases in cell lysates were determined with a dual-luciferase assay system (e1910; Promega). Normalized data were calculated as the quotient of Renilla/Firefly luciferase activities.
Statistical analysis. The relationships between two groups and the numerical values obtained by qRT-PCR were analyzed using the nonparametric Mann-whitney U test or the paired t-test. The relationship among more than three variables and numerical values was analyzed using the Bonferroni adjusted Mann-whitney U test. Spearman's rank test was used to evaluate the relationships among the relative expression levels of miR375 and LDHB mRNA. The Kaplan-Meier method was performed using a median split method in which patients were divided into 2 groups on the basis of whether mRNA expression levels were higher or lower than the median. The log-rank test was used to compare curves. All analyses were performed using expert StatView (version 4, SAS Institute Inc., Cary, NC, USA).
Results

Effect of miR-375 transfection on proliferation and invasion in IMC-3 cells.
The functional significance of miR-375 was evaluated with a gain-of-function assay using miR-375 transfectants. The XTT assay showed significant inhibition of cell proliferation in miR-375 transfectants in comparison with mock and miRNA-control transfectants after 72 h (% of cell proliferation, 60.9±1.0, 100.0±3.3 and 103.0±2.6, respectively, P<0.0001) and after 96 h (% of cell proliferation, 51.0±2.6, 100.0±2.6 and 117.3±8.3, respectively, P<0.0001) (Fig. 1A) .
The Matrigel invasion assay demonstrated that invading cell numbers were significantly decreased in miR-375 transfectants compared to mock and miRNA-control transfectants (% of cell invasion, 46.4±2.4, 100.0±14.2 and 98.7±3.9, respectively, P=0.0005) (Fig. 1B) .
Screening of miR-375 target genes using gene expression analysis. To gain further insight into which protein-coding genes are regulated by miR-375 in IMC-3 cells, we performed comprehensive gene expression analysis with miR-375 transfectants. miRNA-control transfectants that produced raw signal values of <3,000 were excluded before comparisons were made. Fifty-two genes were down-regulated less than -1.0 (Log 2 ratio) in the transfectants (Table II) . The 3'UTR of these downregulated genes were examined for the existence of miR-375 target sites using the TargetScan database. TargetScan revealed that 28 of the 52 genes had putative miR-375 target sites in their 3'UTR (Table II) .
miR-375 regulation of lactate dehydrogenase B (LDHB).
The LDHB gene was chosen for further study because it ranked at the top of the list of candidate genes in the genome-wide gene expression analysis and had one putative miR-375 target site. qRT-PCR revealed that the expression level of LDHB mRNA 1  68  Male  well  4b  0  0  IVB  2  77  Male  Poor  3  0  0  III  3  76  Male  Moderate  3  0  0  III  4  61  Male  well  3  0  0  III  5  54  Male  Poor  3  0  0  III  6  65  Female  Poor  4b  0  0  IVB  7  65  Male  Moderate  4a  0  0  IVA  8  64  Male  Poor  4b  0  0  IVB  9 Fig. 2A) . Protein expression was also markedly reduced in miR-375 transfectants (Fig. 2B) . A luciferase reporter assay was then used to confirm that the predicted binding site was an actual target of miR-375. we used a vector encoding either the total sequence of the LDHB 3'UTR, including the predicted miR-375 target site (positions 171-177), or a vector lacking the miR-375 target site. Luminescence intensity was significantly reduced by trans fection of the entire LDHB 3'UTR, while deletion of positions 171-177 blocked the decrease in luminescence (Fig. 3) .
Effect of LDHB silencing on cell proliferation and invasion.
The functional role of LDHB was examined with loss-offunction studies using IMC-3 cells transfected with two different si-LDHBs. The mRNA and protein levels were markedly reduced in si-LDHB transfectants (Fig. 4A and B) .
The XTT assay revealed significant inhibition of cell proliferation in si-LDHB transfectants in comparison with mock Fig. 5A ) and 96 h (% of cell proliferation: 64.0±1.1, 67.8±2.6, 100.0±1.4 and 96.8±0.8, respectively, P<0.0001; Fig. 5A ).
The Matrigel invasion assay demonstrated that the number of invading cells was significantly lower in the si-LDHB transfectants compared with mock and si-control trans fectants (% of cell invasion, 15.3±2.8, 12.2±3.2, 100.0±14.7 and 77.8±4.8 respectively, P<0.0001) (Fig. 5B) .
Expression levels of miR-375 and LDHB in MSSCC clinical
specimens. The expression level of miR-375 was significantly down-regulated in clinical MSSCC specimens compared with normal tissues (P=0.0006, Fig. 6A ). Conversely, LDHB mRNA was significantly up-regulated in tumor tissues (P= 0.022, Fig. 6A ). The expression of miR-375 was inversely correlated with that of LDHB (Fig. 6B) .
To determine if the levels of LDHB of tumor tissues correlate with the survival of the MSSCC patients, we categorized two groups according to LDHB mRNA expression. As the results of statistical analysis, patients with high LDHB expression group showed worse survival rate than low LDHB expression group (five-year overall survival rate: 35 and 88%, respectively). The log-rank test showed statistically significant difference between the 2 groups (P=0.035; Fig. 7 ).
Discussion
Aberrant expression of miRNAs and uncontrolled gene expression of tumor suppressors and oncogenes contribute to the initiation and development of human cancers (11). we have identified tumor suppressive miRNAs and their associated cancer networks based on miRNA expression signatures (13) (14) (15) (16) . A comparison of these expression signatures (hypopharyngeal and esophageal SCC) with reports from other institutes found that miR-375 is significantly down-regulated in several types of cancers (23, 25, 26, 29, 30 ). An expression signature of MSSCC in our recent study revealed that miR-375 is also reduced (third down-regulated miRNA in this profile) in cancer tissues (data not shown).
Therefore, we investigated the functional significance of miR-375 in MSSCC in this study. The data revealed that restoration of miR-375 suppressed cancer cell proliferation and invasion in IMC-3 cells, confirming results from an analysis of other region of HNSCC (31) . The tumor suppressive function of miR-375 has also been reported with other cancers, such as gastric cancer and liver cancer (23, 25, 26, 32) . These data strongly indicate that miR-375 acts as a tumor suppressor in human cancers.
The unique point of miRNA biogenesis is that one miRNA regulates many protein-coding genes. That is why the elucidation of a miRNA-regulated cancer network is important in understanding human cancer. According to the past studies, miR-375 directly regulates the YWHAZ/14-3-3ζ, PDK1, YAP and JAK2 genes in several cancers (23, 25, 26) . More recently, we also reported that miR-375 directly regulates an oncogene AEG-1/MTDH in HNSCC (31) . Microarray analyses of MSSCC (this study) found that the expression levels of YWHAZ/14-3-3ζ was conspicuously reduced in miR-375 transfectants. There are many studies that YWHAZ/14-3-3ζ functions as an oncogene in several human cancers, including HNSCC (33, 34) . In addition, YWHAZ/14-3-3ζ is located on human chromosome 8q22.3, a region that is frequently the site of copy number gain in HNSCC (35) . overexpression of AEG-1/MTDH, an oncogene under direct regulation of miR-375, was observed in several types of cancers (36) (37) (38) . Many studies have indicated that AEG-1/MTDH contributes to several steps in human oncogenesis, including cancer cell progression, invasion, metastasis, and chemoresistance (39) . It is reported that overexpression of AEG-1/ MTDH promotes activation of the pro-survival pathway of PI3K/AKT via up-regulation of PIP3 (40) . These facts suggest that miR-375 is a direct regulator of the YWHAZ/14-3-3ζ and AEG-1/MTDH oncogenes, and that this phenomenon is important to HNSCC and MSSCC oncogenesis.
The novel finding of this study is that LDHB is directly regulated by miR-375 in MSSCC. LDHB and LDHA are the glycolytic enzymes that catalyze the formation of lactic acid from pyruvate (41) . It has been reported that LDHA is elevated and activated in many cancers (42, 43) . However, a definitive relationship between LDHB and cancer has not been established. In non-small cell lung cancer (NSCLC), the levels of LDHB were significantly elevated in NSCLC sera. Furthermore, the serum levels of LDHB correlated with the clinical stage of NSCLC (41), and concomitant protein expression of LDHB and CCNB1 was a predictor of very poor prognosis in medulloblastoma patients (44) . our data also indicated that mRNA levels of LDHB were elevated in cancer tissues. More interestingly, Kaplan-Meier curves and log-rank tests revealed the high mRNA expression levels of LDHB had a significant adverse effect on survival rate. our results show the possibility that LDHB becomes the prognostic marker of MSSCC. However, our cohort was too small to evaluate this relationship.
A recent study on the role of LDHB in cancer signaling pathways reported that LDHB is a downstream target of mTOR, which is critical for oncogenic mTOR-mediated tumorigenesis (45) . our data revealed that cell proliferation was significantly reduced in si-LDHB transfectants, suggesting that downregulation of miR-375 and up-regulation of LDHB is an indispensable event for MSSCC initiation and development. A detailed study of miR-375-regulated molecular networks is needed for full understanding of human oncogenesis.
In conclusion, the reduction of miR-375 and the increased expression of LDHB are frequent events in MSSCC cancer cells. miR-375 functions as a tumor suppressor and direct regulator of LDHB in MSSCC. The miR-375 regulation of novel cancer pathways could provide new insights into the molecular mechanisms involved in the development of MSSCC and contribute to the development of new therapeutic strategies for the disease. Twenty MSSCC patients were divided into 2 groups on the basis of whether LDHB mRNA expression levels were higher or lower than the median. Kaplan-Meier analysis indicates the correlation between the overall survial of MSSCC patients and mRNA expression levels of LDHB. The log-rank test showed statistically significant difference between the 2 groups. (P= 0.035).
